Sun Pharma acquires Pharmalucence

Sun Pharma acquires Pharmalucence 

 

Mumbai, July 16, 2014: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:

 

SUNPHARMA, BSE: 524715) today announced acquisition of Pharmalucence Inc., by one of its subsidiaries. 

 

Pharmalucence has sterile injectable capacity in the US, supported by strong R&D capabilities. 

 

About Sun Pharma 

 

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 75% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2014, overall revenues were at US$2.7 billion, of which US contributed US$1.6 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com. 

 

Contacts